Resverlogix (RVX) Competitors C$0.06 -0.02 (-26.67%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider Trades RVX vs. PDP, EMH, PMN, DMT, MBX, HBP, BCT, IBT, ACST, and LTYShould you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Pediapharm (PDP), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), Microbix Biosystems (MBX), Helix BioPharma (HBP), BriaCell Therapeutics (BCT), IBEX Technologies (IBT), Acasti Pharma (ACST), and Liberty Biopharma (LTY). These companies are all part of the "biotechnology" industry. Resverlogix vs. Pediapharm Emerald Health Therapeutics ProMIS Neurosciences Small Pharma Microbix Biosystems Helix BioPharma BriaCell Therapeutics IBEX Technologies Acasti Pharma Liberty Biopharma Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings. Does the media favor PDP or RVX? In the previous week, Resverlogix had 1 more articles in the media than Pediapharm. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Pediapharm. Resverlogix's average media sentiment score of 0.75 beat Pediapharm's score of 0.00 indicating that Resverlogix is being referred to more favorably in the news media. Company Overall Sentiment Pediapharm Neutral Resverlogix Positive Which has stronger earnings & valuation, PDP or RVX? Resverlogix has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPediapharmC$11.16M5.95-C$16.15M-C$0.07-4.11ResverlogixN/AN/A-C$10.74M-C$0.05-1.10 Is PDP or RVX more profitable? Company Net Margins Return on Equity Return on Assets PediapharmN/A N/A N/A Resverlogix N/A N/A -34.90% Do analysts recommend PDP or RVX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pediapharm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AResverlogix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor PDP or RVX? Resverlogix received 245 more outperform votes than Pediapharm when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 67.71% of users gave Pediapharm an outperform vote. CompanyUnderperformOutperformPediapharmOutperform Votes6567.71% Underperform Votes3132.29% ResverlogixOutperform Votes31084.01% Underperform Votes5915.99% SummaryResverlogix beats Pediapharm on 7 of the 9 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Resverlogix News Delivered to You Automatically Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVX vs. The Competition Export to ExcelMetricResverlogixBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$15.23MC$189.97MC$5.10BC$4.79BDividend Yield7.02%3.48%7.52%6.57%P/E Ratio-1.10342.67133.4126.18Price / SalesN/A20,319.961,617.651,309.84Price / Cash132.5011.1937.2072.33Price / Book-0.206.924.593.16Net Income-C$10.74M-C$19.41MC$116.16MC$270.20M7 Day PerformanceN/A0.58%-0.97%0.16%1 Month PerformanceN/A2.13%5.32%1.53%1 Year PerformanceN/A23.04%33.76%41.34% Resverlogix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVXResverlogixN/AC$0.06-26.7%N/A-21.4%C$15.23MN/A-1.1019Gap DownPDPPediapharmN/AC$0.30+1.7%N/A+0.0%C$66.36MC$11.16M-4.11N/AEMHEmerald Health TherapeuticsN/AC$0.26-3.8%N/A+0.0%C$52.28MC$13.02M-0.37161PMNProMIS NeurosciencesN/AN/AN/AN/AC$51.48MC$7,558.00-1.786Positive NewsGap UpHigh Trading VolumeDMTSmall PharmaN/AC$0.15-6.3%N/A+0.0%C$50.37MC$-1,162.00-2.1413Gap DownHigh Trading VolumeMBXMicrobix BiosystemsN/AC$0.31-1.6%N/A+23.5%C$42.38MC$23.36M7.75N/AHBPHelix BioPharmaN/AC$0.79-28.2%N/A+245.5%C$38.73MN/A-3.959Gap DownBCTBriaCell TherapeuticsN/AC$1.08+5.9%N/A-82.0%C$38.71MN/A-2.1616Positive NewsIBTIBEX TechnologiesN/AC$1.44flatN/A+51.6%C$35.29MC$8M9.60N/AACSTAcasti PharmaN/AC$0.58+1.8%N/A+0.0%C$25.87MC$115,000.00-1.0732LTYLiberty BiopharmaN/AC$2.00+∞N/A+0.0%C$21.54MN/A-12.66N/AGap Up Related Companies and Tools Related Companies Pediapharm Competitors Emerald Health Therapeutics Competitors ProMIS Neurosciences Competitors Small Pharma Competitors Microbix Biosystems Competitors Helix BioPharma Competitors BriaCell Therapeutics Competitors IBEX Technologies Competitors Acasti Pharma Competitors Liberty Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (TSE:RVX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Resverlogix Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Resverlogix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVX Stock Alerts